MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2507-2515

  Ito, Miki ^a   Mitsuhashi, Kei ^a   Igarashi, Hisayoshi ^a   Nosho, Katsuhiko ^a   Naito, Takafumi ^a   Yoshii, Shinji ^b,c   Takahashi, Hiroaki ^b   Fujita, Masahiro ^b   Sukawa, Yasutaka ^a   Yamamoto, Eiichiro ^a   Takahashi, Taiga ^a   Adachi, Yasushi ^a   Nojima, Masanori ^d   Sasaki, Yasushi ^a   Tokino, Takashi ^a   Baba, Yoshifumi ^e   Maruyama, Reo ^a   Suzuki, Hiromu ^a   Imai, Kohzoh ^d   Yamamoto, Hiroyuki ^f   Shinomura, Yasuhisa ^a   more..

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIYUKAI SAPPORO HOSPITAL   (Japan)

^c Nippon Telegraph and Telegraph and Telephone East Corporation   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BRAF; CIMP; Colon; miR 31; Serrated polyp

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 31; PROTEIN MLH1; TRANSCRIPTION FACTOR RUNX3; BRAF PROTEIN, HUMAN; MICRORNA; MIRN31 MICRORNA, HUMAN;

ADENOMA; ADULT; ARTICLE; ASCENDING COLON; BRAF GENE; CACNA1G GENE; CANCER LOCALIZATION; CDKN2A GENE; CECUM; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CONTINUUM; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATION PHENOTYPE; CYTOLOGICAL DYSPLASIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DYSPLASIA; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF2 GENE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MGMT GENE; MLH1 GENE; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; RECTUM; RECTUM ADENOMA; RUNX3 GENE; SERRATED LESION; SIGMOID; TRADITIONAL SERRATED ADENOMA; CANCER GRADING; COLON POLYP; COLORECTAL TUMOR; COMPARATIVE STUDY; DNA METHYLATION; FOLLOW UP; GENETICS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

ADENOMA; COLONIC POLYPS; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICRORNAS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84920957597     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28920     Document Type: Article

References (51)

1. Edelstein DL, Axilbund JE, Hylind LM, et al. Serrated polyposis: rapid and relentless development of colorectal neoplasia. Gut 2013;62:404-8.
2. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006;131:1400-7.
3. Rosty C, Buchanan DD, Walsh MD, et al. Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am J Surg Pathol 2012;36:876-82.
4. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107:1315-29; quiz 14, 30.
5. Burnett-Hartman AN, Newcomb PA, Potter JD, et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013;73:2863-72.
6. Carr NJ, Mahajan H, Tan KL, et al. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol 2009;62:516-8.
7. Yachida S, Mudali S, Martin SA, et al. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol 2009;33:1823-32.
8. Kim KM, Lee EJ, Kim YH, et al. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am J Surg Pathol 2010;34:667-75.
9. Fujita K, Yamamoto H, Matsumoto T, et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am J Surg Pathol 2011;35:295-304.
10. Han Y, Zhou ZY. Clinical features and molecular alterations of traditional serrated adenoma in sporadic colorectal carcinogenesis. J Dig Dis 2011; 12:193-8.
11. Fu B, Yachida S, Morgan R, et al. Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am J Clin Pathol 2012;138:356-66.
12. Mohammadi M, Kristensen MH, Nielsen HJ, et al. Qualities of sessile serrated adenoma/polyp/lesion and its borderline variant in the context of synchronous colorectal carcinoma. J Clin Pathol 2012;65:924-7.
13. Kaji E, Uraoka T, Kato J, et al. Externalization of saw-tooth architecture in small serrated polyps implies the presence of methylation of IGFBP7. Dig Dis Sci 2012;57:1261-70.
14. Hiraoka S, Kato J, Fujiki S, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology 2010;139:1503-10, 10 e1-3.
15. Gonzalo DH, Lai KK, Shadrach B, et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol 2013;230:420-9.
16. Gaiser T, Meinhardt S, Hirsch D, et al. Molecular patterns in the evolution of serrated lesion of the colorectum. Int J Cancer 2013;132:1800-10.
17. Whitehall VL, Rickman C, Bond CE, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 2012;131:813-20.
18. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
19. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93.
20. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54.
21. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008;3:e3698.
22. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
23. Donehower LA, Creighton CJ, Schultz N, et al. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol 2013;229:99-110.
24. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088-100.
25. Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013;62: 367-86.
26. Goldstein NS. Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol 2006;125:132-45.
27. Rosty C, Hewett DG, Brown IS, et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol 2013;48:287-302.
28. Kriegl L, Neumann J, Vieth M, et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011;24:1015-22.
29. Garcia-Solano J, Conesa-Zamora P, Carbonell P, et al. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int J Cancer 2012;131:1790-9.
30. Conesa-Zamora P, Garcia-Solano J, Garcia-Garcia F, et al. Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. Int J Cancer 2013;132:297-307.
31. Schee K, Boye K, Abrahamsen TW, et al. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 2012;12:505.
32. Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007;72: 397-402.
33. Cekaite L, Rantala JK, Bruun J, et al. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012;14:868-79.
34. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 2011;26:1415-22.
35. Sarver AL, French AJ, Borralho PM, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009;9: 401.
36. Hur K, Toiyama Y, Takahashi M, et al. Micro-RNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013;62:1315-26.
37. Sun D, Yu F, Ma Y, et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem 2013;288:9508-18.
38. Nosho K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014;35:776-83.
39. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-8.
40. Papagiorgis P. Colorectal cancer: dichotomous or continuum model? Perhaps, a combination of both. Gut 2013;62:1519-20.
41. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012;61:794-7.
42. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer, 2010.
43. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival. N Engl J Med 2012;367:1596-606.
44. Nosho K, Yamamoto H, Takahashi T, et al. Correlation of laterally spreading type and JC virus with methylator phenotype status in colorectal adenoma. Hum Pathol 2008;39:767-75.
45. Nosho K, Yamamoto H, Takahashi T, et al. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 2007;28:1364-70.
46. Yamamoto E, Suzuki H, Yamano HO, et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol 2012;181: 1847-61.
47. Slattery ML, Wolff E, Hoffman MD, et al. Micro-RNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes, chromosomes & cancer 2011;50:196-206.
48. Ricciardiello L, Goel A, Mantovani V, et al. Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res 2003;63:787-92.
49. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-60.
50. Sheridan TB, Fenton H, Lewin MR, et al. Sessile serrated adenomas with low-and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". Am J Clin Pathol 2006;126:564-71.
51. Dhir M, Yachida S, van Neste L, et al. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. Int J Cancer 2011;129:1889-98.